Abstract 70P
Background
PD-1 blockade combined with chemotherapy has become the standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without oncogenic drivers. Oncogenic-driven advanced NSCLC showed limited response to PD-1 blockade monotherapy or chemotherapy alone. Whether NSCLC patients with oncogenic drivers showed response to PD-1 blockade plus chemotherapy remains undetermined.
Methods
329 patients with at least one oncogenic driver alteration NSCLC receiving PD-1 plus chemotherapy or each monotherapy were retrospectively identified. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were used to evaluate the therapeutic outcomes differences among patients with different oncogenic drivers.
Results
Totally, 176 patients received PD-1 blockade plus chemotherapy, 60 patients received PD-1 blockade monotherapy and 93 patients received chemotherapy alone were included. Oncogenic drivers including KRAS (31.0%), EGFR (30.4%), HER2 (14.6%), BRAF (10.3%), RET (7.0%) and other mutations (6.7%) were identified. Compared with PD-1 and chemo mono-treatment, patients with oncogenic drivers received PD-1 blockade plus chemotherapy showed significantly better objective response rate (48% vs 22% and 26%; P < 0.001), progression-free survival (median 9.5 vs 3.8 and 5.6 months; P < 0.001) and overall survival (median 25.3 vs 16.8 and 17.0 months; P < 0.001). Multivariate cox regression analysis revealed that PD-1 blockade plus chemotherapy showed dramatically improved benefits both in PFS and OS.
Conclusions
PD-1 blockade plus chemotherapy showed superior efficacy than PD-1 blockade monotherapy or chemotherapy alone in patients with oncogenic-driven advanced NSCLC, particularly in KRAS, EGFR and BRAF subgroup, indicating that PD-1 blockade plus chemotherapy could be considered as optional treatments when these patients without available targeted therapy.
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by grants from the National Natural Science Foundation of China (Nos.82102859, 82172869, 82141101, 82272875 and 12126605).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract